Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fitbits and iPhones used to predict hospitalizations in cancer patients

NCT ID NCT06587100

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study is testing whether wearable activity trackers like Fitbits and iPhones can help predict when cancer patients undergoing radiation therapy might need emergency care or hospitalization. Researchers will collect step counts and other health data from 260 participants to build a model that spots early warning signs. The goal is to see if this approach can keep patients safer and reduce unplanned hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fitbit wearable activity tracker and Apple HealthKit-based devices
What this could lead to
If successful, this could lead to a tool that alerts doctors when a cancer patient's activity drops, helping prevent emergency visits or hospitalizations during radiation therapy.
What could go wrong
This is an early-stage study with only 260 participants, so the model may not work for everyone. It is designed to predict risk, not to treat or cure cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients undergoing non-interventional, standard of care, radiotherapy (RT) at UCSF Department of Radiation Oncology

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 or Karnofsky Performance Scale (KPS) ≤ 50%. * Able to understand study procedures and to comply with them for the entire length of the study. * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. * Diagnosis of invasive malignancy. * Able to ambulate independently (without the assistance of a cane or walker). * Planned treatment with fractionated external beam radiotherapy over at least 5 days (no fractional requirement). * Not a previous participant on this protocol for subsequent courses. Exclusion Criteria: * Participants bound to a wheelchair. * Participants unable to ambulate independently (needing assistance of cane or walker).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymph node neoplasm lymphatic system cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic neoplasm Lymphatic system neoplasm Malignant solid neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.